文献速递结核与非结核分枝杆菌

Xpert MTB/RIF Ultra快速分子检测:改善结核病诊断与利福平耐药检测

The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection.
PubMed 文献 · Clin Microbiol Infect · 2019-03-28

本文为叙述性综述,聚焦Xpert与Xpert MTB/RIF Ultra在结核病诊断中的性能。综述指出Ultra较Xpert灵敏度更高,有利于结核病诊断,但其不能区分活菌与死菌,需谨慎把握适应证与结果解读。肺外结核诊断性能因标本多样性仍需进一步研究。

要点

  • Ultra较Xpert灵敏度更高,有助于结核病诊断。
  • Ultra不能区分活菌与死菌,需谨慎解读结果与把握适应证。
  • 肺外结核诊断性能因标本多样,尚需更多研究确定。

核心结论

  • Ultra较Xpert灵敏度更高,对结核病诊断有益。
  • 高灵敏度检测不能区分活菌与死菌,应谨慎把握适应证与结果解读。
  • 肺外结核诊断的真实性能尚需更多研究确定。

研究设计与样本

  • 叙述性综述,检索同行评议文献中评估Ultra与Xpert诊断性能的出版物。
  • 重点纳入在同一组患者或同一组标本中评估Ultra与Xpert性能、且涉及不同结核病负担环境的研究。

主要发现

  • 已发表研究报道Ultra较Xpert灵敏度增高。
  • Ultra不能区分活菌与死菌。
  • 肺外结核因标本多样性大,真实诊断性能尚需进一步研究。

关键数值与推荐

  • Xpert与Ultra均获世界卫生组织认可。
  • Xpert可直接从临床标本检测结核分枝杆菌及利福平耐药,缩短周转时间、减少患者隔离期并缩短启动抗结核药物时间。
  • Ultra较Xpert显示更高灵敏度并改善利福平耐药检测。

临床怎么用

  • Xpert与Ultra快速普及,推动了分子即时检测(POCT)等新方法与新范式的发展。
  • 使用Ultra高灵敏度检测时,应结合临床谨慎解读结果,注意其不能区分活菌与死菌。

局限性

  • 肺外结核诊断性能因标本多样性大,尚需额外研究确定。
  • 高灵敏度检测不能区分活菌与死菌,需谨慎把握适应证与结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis diagnosis has dramatically improved since the introduction of the rapid molecular test Xpert MTB/RIF (Xpert) detecting M. tuberculosis and rifampicin resistance directly from clinical specimens, therefore shortening the turnaround time, reducing patient's isolation period and decreasing the time to start anti-TB drugs. The new version, Xpert MTB/RIF Ultra (Ultra), displays a higher sensitivity and an improved rifampicin resistance detection. Both tests have been endorsed by the World Health Organisation. AIMS: Xpert and Ultra rapidly became widespread and paved the way for new approaches and new paradigms as well as for the development of molecular point-of-care tests (POCTs). In this narrative review, we aimed to address their performance in the diagnosis of tuberculosis and to discuss the expectations of these tests as well as their limits and the unmet needs. SOURCES: Peer-reviewed publications addressing the diagnostic performance of Ultra and Xpert. CONTENT: We focused on publications that evaluated the performance of Ultra and Xpert on the same group of patients or the same set of specimens in different tuberculosis-burden settings. IMPLICATIONS: The studies published so far reported an increased sensitivity of Ultra when compared to Xpert, which represents a benefit for tuberculosis diagnosis. The fact that such a sensitive assay cannot distinguish between alive and dead bacilli emphasizes that caution should be exercised regarding indications and interpretation of results. Additional studies are needed to determine the true performance for the diagnosis of extrapulmonary tuberculosis because of the great diversity of the specimens.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Opota O, Mazza-Stalder J, Greub G, et al. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clin Microbiol Infect. 2019. PMID: 30928564. doi:10.1016/j.cmi.2019.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。